A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast

@article{Lee2014ARP,
  title={A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast},
  author={O. Lee and K. Page and D. Ivancic and I. Helenowski and V. Parini and M. Sullivan and J. Margenthaler and R. Chatterton and B. Jovanovic and B. Dunn and B. Heckman-Stoddard and Kathleen Foster and M. Muzzio and Julia Shklovskaya and Silvia Skripkauskas and P. Kulesza and D. Green and N. Hansen and K. Bethke and J. Jeruss and R. Bergan and Seema A. Khan},
  journal={Clinical Cancer Research},
  year={2014},
  volume={20},
  pages={3672 - 3682}
}
Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). Methods: Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple… Expand
Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation
Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
Clinical Trials for Ductal Carcinoma In Situ of the Breast
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
...
1
2
3
4
5
...